ADOPT-PRESTAGE: Study Evaluating the Impact of the Program PRESTAGE
Study Details
Study Description
Brief Summary
As the proportion of oral anticancer treatments is continuously increasing, adherence appears as a major issue for patients' outcomes. Poor adherence affects particularly geriatric patients due among others to polypharmacy or cognitive impairment. Thus, the need for educational programs in this population has been regularly emphasized.
PRESTAGE educational program was built after an external and internal analysis of educational needs in elderly patients treated with oral cancer treatments. It implicates a multidisciplinary educational team (nurses, physicians, pharmacists, psychologists, physiologists, social workers...). Six educational workshops were designed with the following endpoints: disease and treatment understanding, treatment management, nutrition and psychological as well as physical well being.
ADOPT-PRESTAGE is a clinical, prospective, interventional, open-label, multicenter, randomized, controlled trial designed to evaluate the impact of PRESTAGE program. It is, to the investigators' knowledge, the first randomized controlled trial evaluating the acceptability and impact (adherence, clinical benefit) of an educational program in an elderly cancer population. The primary endpoint of this trial will be to evaluate adherence using an indirect objective adherence measure: the Medication Event Monitoring System (MEMS). Secondary endpoints include quality of life and evaluation of changes in patients' behaviors.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| No Intervention: Control arm : Information Patients will receive the usual standard information delivered to patients |
|
| Experimental: Intervention arm : Therapeutic educational program Patients will receive the therapeutic educational program "PRESTAGE" |
Behavioral: PRESTAGE
PRESTAGE educational program targets the acquisition by the patients and their caregivers of competencies in (1) a better understanding of their disease and (2) their treatment, (3) a better drug management, including both anticancer and supportive treatments, (4) maintenance of a good nutritional status, (5) general health and psychological well being and (6) physical well being. After an individual educational diagnosis, each patient will be proposed an individualized educational program consisting in 1 to 6 of these workshops. An individualized final interview - entitled educational synthesis - will assess patient's skills and satisfaction.
|
Outcome Measures
Primary Outcome Measures
- Adherence evaluated by MicroElectronic Monitoring System [at 4 months (after intervention or information)]
Adherence will be evaluated with MicroElectronic Monitoring System. A composite score such as described by Thivat et al. in 2013 will be used.
Secondary Outcome Measures
- Adherence evaluated by Morisky questionnaires [4 months to 12 months]
Results to Morisky questionnaires will be evaluated such as adherence with MEMS, until 12 months.
- Adherence evaluated by pharmacy medication refill -based adherence [4 months to 12 months]
Results to pharmacy medication refill -based adherence will be evaluated such as adherence with MEMS, until 12 months.
- Health-related quality of life evaluated by QLQ-C30 quality of life questionnaire [4 months to 12 months]
- Health-related quality of life evaluated by the QLQ-ELD14 quality of life questionnaire [4 months to 12 months]
- Health-related quality of life evaluated by the EORTC quality of life questionnaire [4 months to 12 months]
- Changes in patients' behaviors evaluated by questionnaires [4 months to 12 months]
Beliefs about Medication questionnaire and satisfaction with medication questionnaires
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients older than 70 years,
-
For which oral anticancer therapy has been initiated within the previous 45 days or will be started within 45 days
-
For any type of cancer, solid or hematologic, any stage
-
Estimated life expectancy> 6 months
-
Affiliation to social security or equivalent
-
Patients who can answer questionnaires and protocol evaluations
-
Informed consent signed by patients
-
Domiciled within 50 km around the investigating center
Exclusion Criteria:
-
For patients with breast cancer, exclusive treatment with hormone therapy
-
First-generation Hormone Therapy in Prostate Cancer
-
Patient not available for regular follow-up whatever the cause (geographic, family, social, psychological)
-
Any serious condition, ie serious physical or mental, leading to a disability permanent and likely to prevent the proper course of treatment
-
Patient deprived of liberty or under guardianship
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Service de neuro-oncologie, Hôpital Pierre Wertheimer, HCL | Bron | France | 69500 | |
| 2 | Service de Gériatrie, Centre Hospitalier de Givors | Givors | France | 69700 | |
| 3 | Service d'oncologie médicale, Centre Hospitalier Universitaire de Grenbole | La Tronche | France | 38700 | |
| 4 | Service de Médecine du vieillissement, Hôpital Edouard Herriot, HCL | Lyon | France | 69003 | |
| 5 | Service de médecine du vieillissement, Hôpital de la Croix-Rousse, HCL | Lyon | France | 69004 | |
| 6 | Service d'oncologie médicale, Cnetre Léon Bérard | Lyon | France | 69373 cedex 08 | |
| 7 | Service d'oncologie, Centre Hospitalier Annecy Genevois | Metz-Tessy | France | 74370 | |
| 8 | Service de Médecine du vieillissement, Centre Hospitalier Lyon Sud (Hospices Civils de Lyon) | Pierre-Bénite | France | 69310 | |
| 9 | service de gériatrie, Hôpital de la Charité, Centre Hospitalier Universitaire de St-Etienne | Saint-Étienne | France | 42100 |
Sponsors and Collaborators
- Hospices Civils de Lyon
Investigators
- Study Chair: Olivia LE SAUX, Hospices Civils de Lyon
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 69HCL16_0149